Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion

Sean P David, David R Strong, Adam M Leventhal, Molly A Lancaster, John E McGeary, Marcus R Munafò, Andrew W Bergen, Gary E Swan, Neal L Benowitz, Rachel F Tyndale, David V Conti, Richard A Brown, Caryn Lerman, Raymond Niaura

Research output: Contribution to journalArticle (Academic Journal)peer-review

23 Citations (Scopus)

Abstract

To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.
Original languageEnglish
JournalAddiction
DOIs
Publication statusPublished - 14 Aug 2013

Bibliographical note

© 2013 Society for the Study of Addiction.

Structured keywords

  • Brain and Behaviour
  • Tobacco and Alcohol

Fingerprint Dive into the research topics of 'Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion'. Together they form a unique fingerprint.

Cite this